focus -WSS

focus

author：knowledge 2025-10-01 21:33:21 - browse：41

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Alabama IVF ruling threatens families facing fatal genetic disease

hotspot

WSS

Alabama IVF ruling threatens families facing fatal genetic disease

Judge sides with young activists in first

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Aspartame and sugar

Dozens dead from Maui wildfires: What we know about the victims

Antivenom research: Lessons from HIV applied in search for universal antidote

hotspot

focus

hotspot

What does generative AI mean for health care? We asked experts

Dozens dead from Maui wildfires: What we know about the victims

Moonlake's readout produced a cash windfall. Risks remain

Illumina slashes 2023 revenue projections yet again

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT readers on older presidents, polypills, Medicare, and more

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Schizophrenia gene found to be linked to cells' energy dysfunction

Duchenne breakthrough therapy leaves behind pioneering families

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

hotspot

Dario to buy mental health app maker Twill in cash and stock deal

A new nitrogen execution bill also undermines medical licensing

Alabama IVF ruling threatens families facing fatal genetic disease

Patients, digital health players weigh in on FTC's data privacy plan

BMS, looking to build heart drug business, turns to AI for diagnosis

Surge in Apellis stock fueled by confidence in safety of its eye drug

hotspot

leisure time

hotspot

knowledge